-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 19, Hisun Pharmaceutical issued an announcement stating that the company had recently received tofacitib citrate tablets to obtain a drug registration certificate.
Tofacitinib citrate tablets are suitable for moderate to severely active rheumatoid arthritis (RA) adult patients with insufficient or intolerable methotrexate efficacy, and can be improved with methotrexate or other non-biological improvements Disease antirheumatic drugs (DMARD) are used in combination.
Tofacitinib citrate was developed by Pfizer and was approved by the US FDA on November 6, 2012, under the trade name XELJANZ®.
On January 15, 2019, the State Food and Drug Administration accepted the company's application for drug registration of tofacitib citrate tablets.